Conference Correspondent

Conference Correspondent

Epratuzumab is an anti-CD22 monoclonal antibody that modulates B-cell activation and has demonstrated clinically relevant improvements in disease activity in patients with moderate-to-severe systemic lupus erythematosus (SLE) in the phase 2b EMBLEM study (Wallace DJ, et al. Ann Rheum Dis. 2013 Jan 12. Epub ahead of print)
Patients with systemic lupus erythematosus (SLE) frequently require corticosteroids as standard therapy.
Large-scale phase 3 clinical trials have already demonstrated the clinical efficacy of belimumab (Benlysta) in patients with systemic lupus erythematosus (SLE), which served as the basis for the US Food and Drug Administration approval of this medication for adult patients with active, autoantibody-positive SLE who are receiving standard therapy.
Belimumab (Benlysta) is a human monoclonal antibody that inhibits B-lymphocyte stimulator that is approved by the US Food and Drug Administration for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy.
Elevation of interferon type I (IFN-I) is associated with more severe disease in patients with systemic lupus erythematosus (SLE), although the relationship between elevated levels of IFN-I and SLE disease activity over time has not been defined.
Lupus nephritis is frequently associated with a poor long-term prognosis in patients with systemic lupus erythematosus (SLE).
Disease-specific patient-reported outcome (PRO) tools would be useful in the management of a number of rheumatologic conditions, including rheumatoid arthritis (RA), psoriatic arthritis, and systemic lupus erythematosus (SLE).
The pathogenesis of systemic lupus erythematosus (SLE) is characterized by complex immune dysfunction, including aberrant T-cell responses that result in tissue damage and terminal organ failure.
There is evidence from animal models of lupus nephritis that the combination of CTLA4-immunoglobulin (Ig)G plus cyclophosphamide can reverse this disease.
Approximately 50% of patients with systemic lupus erythematosus (SLE) have a serious infection during their disease course, and infections are the leading causes of hospitalization and mortality in these patients.
Page 6 of 7
Results 51 - 60 of 61
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME